



## Food and Drug Administration Advisory Committee Member Acknowledgment of Financial Interests

Name of Advisory Committee Member: Dr. Kenneth Berns, M.D., M.P.H.

Committee: Cellular Tissue and Gene Therapies Advisory Committee (CTGTAC)

Meeting Date: September 2-3, 2021

I acknowledge that contingent upon public disclosure of the following financial interest(s) related to the meeting topic: The CTGTAC committee will meet in open session on both days to discuss the toxicity risks of adeno-associated virus (AAV) vector-based gene therapy products. The discussion topics include safety issues identified during preclinical and/or clinical evaluation, and oncogenicity risks due to vector genome integration. I may be considered for participation in the advisory committee meeting described above.

| <u>Type of Interest</u>                               | <u>Nature</u> | <u>Magnitude</u> |
|---|---------------|------------------|
| I. Personal/Immediate Family                          |               |                  |
| SPDR Bloomberg Health Care Select Sector Fund/(b) (4) | Affected Firm | \$0 - \$5,000    |
| (b) (4)   | Affected Firm | \$5001 – 10,000  |

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

-----S-----  
\_\_\_\_\_  
Signature

06/26/21  
\_\_\_\_\_  
Date

Kenneth Berns, M.D., Ph.D.